|
|
News from the University of Arkansas for Medical Sciences
Japanese
TV Crew Interviews UAMS’s Bart Barlogie, M.D., Ph.D.
| DEC.
5, 2002 | A Japanese television crew interviewed Bart Barlogie,
M.D., Ph.D., yesterday at the University of Arkansas for
Medical Sciences (UAMS).
Dr. Barlogie is director of the
Myeloma Institute for Research and Technology at UAMS. The
interview will appear on the Japanese network Nippon Hoso
Kioka (NHK) as part of a report on the use of Thalidomide in
treatment of multiple myeloma.
Dr. Barlogie was the first physician to administer
Thalidomide for the rare bone marrow disease in 1997, and he
was the principal investigator for a two- year study of the
once-banned drug. The study demonstrated that the drug has a
particular anti-angiogenic effect on myeloma tumors, reducing
the cancer cells and improving survival rates. The discovery
represented a resurrection for Thalidomide after the stigma
attached to it when it caused thousands of birth defects in
England and Canada. It is the first new drug for myeloma in
nearly 40 years.
"It provided, for the first time, a means of treating
patients when there was no life," Barlogie told NHK
interviewer Kayoko Mitsumatsu. He will report on the long-term
follow-up of study patients at the American Society of
Hematology meeting in Philadelphia, which begins Friday.
"These patients (highlighted by the study results) should
have all been dead within six months. So this is a major
advance, and I think every patient with myeloma in the entire
world should have access to it, along with other drugs,"
he said.
|
Multiple
myeloma expert Bart Barlogie, M.D., Ph.D., gave an interview
to a Japanese television network Dec. 4. (JohnPaul
Jones)
(Click on image for larger view.)
|
Subscribe to "Myeloma Advances Today,"
a free e-mail newsletter. Send a message to UAMS
Today with "subscribe myeloma" in the
subject line.
|
|
|
|
|
|
|
Mitsumatsu, who is based in Los Angeles, joined NHK Program
Director Kouichi Matsumoto, videographer Yu Nambu, and video
engineer Masahiro Murakami for the shoot in Little Rock. The
interview will air as one segment of the half-hour program
"Close-Up Gendai" (Close-Up Today) Thurs., Dec. 12,
at 7:30 p.m.
"In Japan, thalidomide is not managed carefully or
properly, even though it is widely used right now,"
Matsumoto said. Physicians in Japan legally import thalidomide
for their patients without the oversight of the nation's drug
regulatory agency. "Therefore, we came to here to learn
how in the United States, people have established a system so
that the drug is managed properly so that it will not cause
any further tragedy while also using it effectively on a
certain disease."
The crew was to interview officials with the U.S. Food and
Drug Administration in Washington before returning to Japan.
It's not the first time Dr. Barlogie and the Myeloma Institute
have received international television exposure. He was
featured on a program for Turkish television two years ago,
and will be part of a German TV program scheduled for March
2003. Dr. Barlogie was also the focus of a NOVA episode on the
Public Broadcasting System entitled "Cancer
Warrior."
Links on This Page
Bart Barlogie, M.D., Ph.D.:
http://www.acrc.uams.edu/profiles/barlogie.htm
Myeloma Institute for Research and Treatment: http://myeloma.uams.edu/index.htm
Novel Regimens Emerging: http://www.uams.edu/info/Updates/April02/myeloma.htm
UAMS To Create Myeloma Institute: http://www.uams.edu/today/081601/myeloma.htm
© 2002 University of Arkansas for Medical Sciences (UAMS). A
single copy of these materials may be reprinted for
noncommercial personal use only. "UAMS," "UAMS
Online," "UAMS Today," "UAMS Update,"
"uams.edu," and "Here’s to Your Health"
are marks of UAMS.
|
|
|
|
04/21/04 |
E-mail This Article